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The Case for High Returns:
A Study of the Pharmaceutical Industry
David Taylor and David Russe1I*, Department of Business Administration
This project analyzes the abnormal returns that the larger pharmaceutical
firms generate by studying such variables as R&D expenditures, demographics, and
market structure and their effect on the abnormal returns pharmaceutical firms
generate for their stockholders. A company's abnormal return is the difference
between the return on that company's common stock and the market return. The
principal hypothesis is that investment in research and development, the aging
population, and increasing generic market share, significantly affect the abnormal
returns generated by pharmaceutical firms. This project will also examine how
other aspects of the pharmaceutical industry distinguish it from other industries
and how these characteristics may account for the abnormal returns that
pharmaceutical firms generate for their shareholders.

